Literature DB >> 29209568

Phenotype and tissue distribution of CD28H+ immune cell subsets.

Joel Crespo1,2, Linda Vatan1, Tomasz Maj1, Rebecca Liu3, Ilona Kryczek1, Weiping Zou1,4,2,5.   

Abstract

CD28H is a newly discovered co-receptor of the human B7 family. CD28H interacts with its ligand B7-H5 and regulates T cell response. Here we showed that CD28H was not expressed on granulocytes, monocytes, myeloid dendritic cells (MDCs), and B cells, but constitutively expressed with moderate levels on memory T cells and with high levels on naïve T cells, innate lymphoid cells (ILCs), natural killer (NK) cells, and plasmacytoid dendritic cells (PDCs) in human peripheral blood. Similar CD28H+ cell profile existed in secondary lymphoid organs and pathological tissues including multiple types of cancers. Further analysis demonstrated that CD28H+ naïve and CD28H+ memory T cells were characterized with increased naïve feature and less effector functional phenotype, respectively. High levels of constitutive CD28H expression on naïve T cells and innate immune cells suggest a potential role of CD28H in innate and adaptive immunity.

Entities:  

Keywords:  Antigen presenting cell; CD28H; Innate lymphoid cells; dendritic cell; immunity; memory T cell; naïve T cell; tumor

Year:  2017        PMID: 29209568      PMCID: PMC5706608          DOI: 10.1080/2162402X.2017.1362529

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  19 in total

1.  Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells.

Authors:  J Galea-Lauri; D Darling; S U Gan; L Krivochtchapov; M Kuiper; J Gäken; B Souberbielle; F Farzaneh
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

2.  CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells.

Authors:  D Nandi; J A Gross; J P Allison
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 4.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

5.  Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.

Authors:  W Zou; V Machelon; A Coulomb-L'Hermin; J Borvak; F Nome; T Isaeva; S Wei; R Krzysiek; I Durand-Gasselin; A Gordon; T Pustilnik; D T Curiel; P Galanaud; F Capron; D Emilie; T J Curiel
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

6.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

7.  HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.

Authors:  Ruihua Zhao; Jordan M Chinai; Susan Buhl; Lisa Scandiuzzi; Anjana Ray; Hyungjun Jeon; Kim C Ohaegbulam; Kaya Ghosh; Aimin Zhao; Matthew D Scharff; Xingxing Zang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

Review 8.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

Review 9.  Inhibitory B7-family molecules in the tumour microenvironment.

Authors:  Weiping Zou; Lieping Chen
Journal:  Nat Rev Immunol       Date:  2008-06       Impact factor: 53.106

10.  CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis.

Authors:  Florence Roan; Thomas A Stoklasek; Elizabeth Whalen; Jerry A Molitor; Jeffrey A Bluestone; Jane H Buckner; Steven F Ziegler
Journal:  J Immunol       Date:  2016-01-29       Impact factor: 5.422

View more
  7 in total

1.  CD28H expression identifies resident memory CD8 + T cells with less cytotoxicity in human peripheral tissues and cancers.

Authors:  Yu Tian; Yi Sun; Fan Gao; Michelle R Koenig; Alexander Sunderland; Yuki Fujiwara; Robert J Torphy; Lieping Chen; Barish H Edil; Richard D Schulick; Yuwen Zhu
Journal:  Oncoimmunology       Date:  2018-11-05       Impact factor: 8.110

2.  CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7+ Tumor Cells.

Authors:  Xiaoxuan Zhuang; Eric O Long
Journal:  Cancer Immunol Res       Date:  2019-04-24       Impact factor: 11.151

3.  Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis.

Authors:  C Zhong; Q Lang; J Yu; S Wu; F Xu; Y Tian
Journal:  Clin Exp Immunol       Date:  2020-02-04       Impact factor: 4.330

4.  B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma.

Authors:  Qi Chen; Jianxin Wang; Wei Chen; Qi Zhang; Tao Wei; Yue Zhou; Xingyuan Xu; Xueli Bai; Tingbo Liang
Journal:  Cancer Sci       Date:  2019-01-16       Impact factor: 6.716

Review 5.  Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.

Authors:  Honggang Ying; Jian Xu; Xiaozhen Zhang; Tingbo Liang; Xueli Bai
Journal:  EBioMedicine       Date:  2022-04-16       Impact factor: 11.205

6.  HHLA2 promotes tumor progression by long non‑coding RNA H19 in human gallbladder cancer.

Authors:  Yizhou Zhang; Hanrong Li; Chao Lv; Baokang Wu; Yang Yu; Chongli Zhong; Qi Lang; Zhiyun Liang; Yang Li; Yu Shi; Jian Zhang; Feng Xu; Yu Tian
Journal:  Int J Oncol       Date:  2022-08-03       Impact factor: 5.884

7.  KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.

Authors:  Abdulla Berjis; Julie C Konge; Kathleen M Mahoney; Alyssa N Klee; Rupal S Bhatt; Samuel S Freeman; Chun-Hau Chen; Opeyemi A Jegede; Paul J Catalano; Jean-Christophe Pignon; Maura Sticco-Ivins; Baogong Zhu; Ping Hua; Jo Soden; Jie Zhu; David F McDermott; Antonio R Arulanandam; Sabina Signoretti; Gordon J Freeman
Journal:  Cancer Immunol Res       Date:  2020-11-23       Impact factor: 12.020

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.